TY - JOUR
T1 - Mutations in PIK3R1 cause SHORT syndrome
AU - Dyment, David A.
AU - Smith, Amanda C.
AU - Alcantara, Diana
AU - Schwartzentruber, Jeremy A.
AU - Basel-Vanagaite, Lina
AU - Curry, Cynthia J.
AU - Temple, I. Karen
AU - Reardon, William
AU - Mansour, Sahar
AU - Haq, Mushfequr R.
AU - Gilbert, Rodney
AU - Lehmann, Ordan J.
AU - Vanstone, Megan R.
AU - Beaulieu, Chandree L.
AU - Majewski, Jacek
AU - Bulman, Dennis E.
AU - O'Driscoll, Mark
AU - Boycott, Kym M.
AU - Innes, A. Micheil
N1 - Funding Information:
The authors would firstly like to thank the study participants and their families—without their participation, this work would not have been possible. This work was funded by the Government of Canada through Genome Canada, the Canadian Institutes of Health Research (CIHR), and the Ontario Genomics Institute (OGI-049). Additional funding was provided by Genome Quebec and Genome British Columbia. M.O.D. is a Senior Cancer Research UK (CR-UK) Fellow whose lab is supported by CR-UK, the Medical Research Council (UK), and Leukaemia Lymphoma Research (UK). A.C.S. is supported by a CIHR postdoctoral fellowship. D.A.D and K.M.B are the recipients of a CIHR Clinical Investigator award from the Institute of Genetics. This work was selected for study by the FORGE Canada Steering Committee, consisting of K.M.B., J. Friedman, J. Michaud, F. Bernier, M. Brudno, B. Fernandez, B. Knoppers, M. Samuels, and S. Scherer.
PY - 2013/7/11
Y1 - 2013/7/11
N2 - SHORT syndrome is a rare, multisystem disease characterized by short stature, anterior-chamber eye anomalies, characteristic facial features, lipodystrophy, hernias, hyperextensibility, and delayed dentition. As part of the FORGE (Finding of Rare Disease Genes) Canada Consortium, we studied individuals with clinical features of SHORT syndrome to identify the genetic etiology of this rare disease. Whole-exome sequencing in a family trio of an affected child and unaffected parents identified a de novo frameshift insertion, c.1906-1907insC (p.Asn636Thrfs18), in exon 14 of PIK3R1. Heterozygous mutations in exon 14 of PIK3R1 were subsequently identified by Sanger sequencing in three additional affected individuals and two affected family members. One of these mutations, c.1945C>T (p.Arg649Trp), was confirmed to be a de novo mutation in one affected individual and was also identified and shown to segregate with the phenotype in an unrelated family. The other mutation, a de novo truncating mutation (c.1971T>G [p.Tyr657]), was identified in another affected individual. PIK3R1 is involved in the phosphatidylinositol 3 kinase (PI3K) signaling cascade and, as such, plays an important role in cell growth, proliferation, and survival. Functional studies on lymphoblastoid cells with the PIK3R1 c.1906-1907insC mutation showed decreased phosphorylation of the downstream S6 target of the PI3K-AKT-mTOR pathway. Our findings show that PIK3R1 mutations are the major cause of SHORT syndrome and suggest that the molecular mechanism of disease might involve downregulation of the PI3K-AKT-mTOR pathway.
AB - SHORT syndrome is a rare, multisystem disease characterized by short stature, anterior-chamber eye anomalies, characteristic facial features, lipodystrophy, hernias, hyperextensibility, and delayed dentition. As part of the FORGE (Finding of Rare Disease Genes) Canada Consortium, we studied individuals with clinical features of SHORT syndrome to identify the genetic etiology of this rare disease. Whole-exome sequencing in a family trio of an affected child and unaffected parents identified a de novo frameshift insertion, c.1906-1907insC (p.Asn636Thrfs18), in exon 14 of PIK3R1. Heterozygous mutations in exon 14 of PIK3R1 were subsequently identified by Sanger sequencing in three additional affected individuals and two affected family members. One of these mutations, c.1945C>T (p.Arg649Trp), was confirmed to be a de novo mutation in one affected individual and was also identified and shown to segregate with the phenotype in an unrelated family. The other mutation, a de novo truncating mutation (c.1971T>G [p.Tyr657]), was identified in another affected individual. PIK3R1 is involved in the phosphatidylinositol 3 kinase (PI3K) signaling cascade and, as such, plays an important role in cell growth, proliferation, and survival. Functional studies on lymphoblastoid cells with the PIK3R1 c.1906-1907insC mutation showed decreased phosphorylation of the downstream S6 target of the PI3K-AKT-mTOR pathway. Our findings show that PIK3R1 mutations are the major cause of SHORT syndrome and suggest that the molecular mechanism of disease might involve downregulation of the PI3K-AKT-mTOR pathway.
UR - http://www.scopus.com/inward/record.url?scp=84880316181&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2013.06.005
DO - 10.1016/j.ajhg.2013.06.005
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 23810382
AN - SCOPUS:84880316181
SN - 0002-9297
VL - 93
SP - 158
EP - 166
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 1
ER -